| Australian Skin Cancer Genetic Study Seeks to Recruit 20K Additional Participants |
| Published on Sep 16, 2019 |
 |
| Castle Biosciences Q2 Revenues Up 168 Percent |
| Published on Sep 03, 2019 |
|
Minimal Residual Disease Monitoring with an NGS-Based FLT3 Mutation Assay
Watch this on-demand webinar by Invivoscribe to learn about minimal residual disease detection of B-lymphoid and plasma cell neoplasms using a next-generation sequencing based assay. Download it from GenomeWeb’s Webinar library |
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου